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Anti-tubercular activityAbstract In the present investigation we have utilized the 3-arylsydnones 1a–c to couple two
biodynamic moieties in amide derivatives 7–10. The 3-arylsydnones were brominated to
4-bromo-3-arylsydnones 2a–c which further were reacted with benzotriazole/benzothiazolin-2-thi-
one/morpholine/diphenylamine to the corresponding ﬁnal compounds. The structures of the amide
derivatives were conﬁrmed by the spectral (IR, 1H NMR and Mass) and analytical data. Further,
these were subjected to the antitubercular activity against Mycobacterium tuberculae (H37Rv). The
morpholine 7a–c and benzotriazole 8a–c derivatives have exhibited good inhibition.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Tuberculosis (TB), a highly infectious disease primarily caused
by Mycobacterium tuberculosis, is one of the oldest recorded
human afﬂictions and remains today a leading cause of impov-
erishment, human suffering and death (The Global Plan to
Stop TB, 2006; Smith, 2003; Schluger, 2005; Tiruviluamala
and Reichmann, 2002). It is estimated that one person in every10 of the two billion people infected worldwide will develop
infectious TB. A number of factors have led to the reduction
in the successful treatment of the disease. These include a
lengthy (6–9 months) multi-drug treatment program, the mis-
use or mismanagement of which can lead to the development
of multi or extensive drug resistant TB (MDRTB or XDRTB)
and the co-infection of TB with the human immunodeﬁciency
virus (HIV) (Copp and Pearce, 2007). A new anti-TB drug
needs to show the well pharmacokinetic distribution and per-
meation into lung tissue and cells. Furthermore, it is also de-
sired that the novel candidate exhibits the potent bactericidal
activity both against exponential and stable phase ofM. tuber-
culosis in vivo. In addition, it is ideal that the novel agent pos-
sesses narrow anti-microbial spectrum specialized only against
Mycobacterial species. Among the various classes of nitrogen
heterocyclic compounds, secondary amines display a broad
spectrum of biological activities (Rao et al., 2010).
Synthetic utility of sydnones to couple pharmacologically important heterocycles for antitubercular activity 901Amongst the mesoinoic compounds studied so far, syd-
nones have attained importance due not only to their struc-
tural features and chemical properties, but also to their
biological properties. During past years many interesting
data have been obtained on the structure (Cooper et al.,
2005; Hasek et al., 1979), reactivities (Dumitrascu et al.,
2002; Cherepanov and Kalinin, 2000), physicochemical prop-
erties (Sasaki and Ishibashi, 1990; Handa et al., 1997) and
pharmacological actions (Moustafa et al., 2004; Dunkley
and Thoman, 2003; Anto et al., 1994; Kier and Roche,
1967). One of the resonance hybrids of the sydnone bears
a partial negative charge on the C4 carbon. Accordingly,
electrophilic substitution for instance halogenation (Tien
et al., 1979), nitration (Hashimoto and Ohta, 1957), acyla-
tion (Tien and Ohta, 1972) and sulfonation (Vasileva and
Yashunskii, 1958a,b) occurs at 4th position. Sydnones have
played a crucial role in the development of theory in hetero-
cyclic chemistry and have been used extensively as synthons
in organic synthesis. Due to their 1,3-dipolar nature they
easily undergo thermal and photochemical 1,3 dipolar cyclo-
addition reaction to transform into various types of hetero-
cycles, such as 1,3,4-oxadiazole, pyrazolines, pyrazoles,
phenylindazoles and tetrazines. Further, the sydnones were
also used as synthons for the ring conversion into tetrahyd-
rocarbazoles by acid hydrolysis followed by the reaction
with cycloalkanones (Ohta and Kato, 1969). Resonance con-
tributing structure responsible for such 1,3-dipolar cycload-
dition is as shown below.
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This fact made us to utilize the ring conversion of 4-bromo-
3-arylsydnones to the amides derivatives with biopotent sec-
ondary amines by the mild reaction.
2. Experimental
2.1. General
Melting points were determined in open capillaries. The IR
spectra were recorded on a Nicolet Impact 5200 USA FT IR
using KBr pellets. 1H NMR spectra were recorded on a Bruker
Varian 300-MHz FT NMR spectrometer with TMS as an
internal standard. EI mass spectral analyses were recorded
on a Shimadzu Japan QP2010 S model spectrometer and ele-
mental analyses were carried out using a Heraus CHN rapid
analyzer. The purity of the compounds was checked by thin
layer chromatography (TLC) on silica gel plate using benzene
and ethyl acetate. The pharmacological evaluation was carried
out at the Department of Microbiology and Immunology,
NGH College of Dental sciences, Belgaum, Karnataka, India.
The log P values have been calculated using the OSIRIS
molecular property explorer software for the structural ana-
logues of the synthesized compounds and are uncorrected. 4-
Bromo-3-arylsydnone (2a–c) required for the present work
and the title compounds were prepared according to reported
methods (Kamble and Badami, 2002; Puranik and Suschitzky,
1967).2.2. General procedure for the preparation of amide derivatives
(7–10)
2.2.1. Preparation of (7a–c)
A mixture of 4-bromo-3-arylsydnone (2a–c) (0.01 mol) and
secondary amine (3) (0.02 mol) was reﬂuxed for 2 h at
130 C. The progress of the reaction was followed by TLC
using toluene and methanol as eluents. After completion of
the reaction, the mixture was concentrated on water bath
and the solid obtained was further recrystallised using ethanol
to get the yellow needles of the title compound (7a–c).
2.2.2. Preparation of (8–10)
A mixture of 4-bromo-3-arylsydnone (2a–c) (0.01 mol) and
secondary amine (4–6) (0.02 mol) was taken in dry ethanol
and reﬂuxed for 12 h on water bath. The progress of the reac-
tion was followed by TLC using toluene and methanol as elu-
ents. After completion of the reaction, the mixture was
concentrated on water bath and the solid obtained was further
recrystallised using ethanol to get the yellow needles of title
compound (8–10).
2.2.2.1. 1,2-Dimorpholino-2-(phenylamino)ethanone (7a).
Yield 80% m.p. 205 C. IR (KBr): m = 3377 (1NH), 3180
(CH aromatic), 2961 (CH aliphatic), 1610 (1C‚O) cm1. 1H
NMR (300 MHz, CDCl3-d6, 25 C, TMS): d = 3.32–3.39 (m,
8H, N–CH2 morpholine ring), 3.60–3.67 (m, 8H, O–CH2 mor-
pholine ring), 4.45 (s, 1H, NH, D2O exchangeable), 4.74 (s,
1H, CH), 6.43–7.04 (m, 5H, aromatic ring) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS): d = 50.1 (CH2), 51.0
(CH2), 71.1 (CH2), 71.3 (CH2), 80.8 (CH), 112.3, 112.5,
116.9, 129.3, 129.5, 143.5 (phenyl carbons), 169.1 (C‚O);
MS: m/z= 305 (M+, 20), 302 (15), 291 (20), 274 (40), 264
(15), 246 (18), 231 (25), 218 (25), 205 (35), 191 (40), 179 (20),
163 (42), 147 (55), 137 (35), 123 (45), 109 (60), 100 (70), 85
(71), 83 (80), 70 (50), 57 (70), 43 (100), 41 (68), 40 (20). Anal.
for C16H23N3O3 calcd. C 62.93, H 7.59, N, 13.76; Found C
62.90, H 7.57, N, 13.74.
2.2.2.2. 2-(p -Tolylamino)-1,2-dimorpholinoethanone (7b).
Yield 75% m.p. 134 C. IR (KBr): m = 3360 (1NH), 3170
(CH aromatic), 2951 (CH aliphatic), 1615 (1C‚O) cm1. 1H
NMR (300 MHz, CDCl3-d6, 25 C, TMS): d = 2.39 (s, 3H,
CH3), 3.15–3.27 (m, 8H, N–CH2 morpholine ring), 3.48–3.53
(d, 8H, O–CH2 morpholine ring), 4.47 (s, 1H, NH, D2O
exchangeable), 4.77 (s, 1H, CH), 7.22–7.28 (m, 4H, aro-
matic ring) ppm; 13C NMR (100 MHz, DMSO-d6, 25 C,
TMS): d = 20.9 (CH3), 50.3 (CH2), 50.2 (CH2), 71.1 (CH2),
71.3 (CH2), 80.8, 112.2, 112.5, 126.1, 130.0, 130.2, 140.5 (phenyl
carbons), 169.3 (C‚O); MS: m/z= 319 (M+, 15), 317 (20),
316 (30), 302 (15), 291 (20), 274 (40), 264 (15), 246 (18), 231
(25), 218 (25), 205 (35), 191 (40), 179 (20), 163 (42), 147 (55),
137 (35), 123 (45), 109 (60), 100 (70), 85 (71), 83 (80), 70 (50),
57 (100), 43 (70), 41 (68), 40 (20). Anal. for C17H25N3O3 calcd.
C 63.93, H 7.89, N, 13.16; Found C 63.90, H 7.87, N, 13.14.
2.2.2.3. 2-(4-Bromophenylamino)-1,2-dimorpholinoethanone
(7c). Yield 86% m.p. 170 C. IR (KBr): m = 3408
(1NH), 3286 (CH aromatic), 2919 (CH aliphatic), 1638
(1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 3.30–3.37 (m, 8H, N–CH2 morpholine ring),
902 T. Taj et al.3.62–3.65 (m, 8H, O–CH2 morpholine ring), 4.47 (s, 1H, NH,
D2O exchangeable), 4.89 (s, 1H, CH), 6.32–7.26 (m, 5H, aro-
matic ring) ppm; 13C NMR (100 MHz, DMSO-d6, 25 C,
TMS): d = 50.1(CH2), 51.1(CH2), 71.1 (CH2), 71.3(CH2),
80.8 (CH), 111.5, 114.5, 114.7, 132.6, 132.7, 142.5 (phenyl car-
bons), 169.2 (C‚O); MS: m/z= 385 (M+2, 6), 383 (M+, 20),
356 (10), 358 (10), 338 (30), 262 (30), 199 (10), 183 (40), 171
(35), 155 (65), 132 (35), 111 (30), 112 (65), 95 (40), 84 (50),
71 (52), 69 (75), 65 (70), 55 (70), 43 (100), 41 (60). Anal. for
C16H22BrN3O3 calcd. C 50.01, H 5.77, N, 10.94; Found C
50.00, H 5.75, N, 10.95.
2.2.2.4. 1,2-Di(1H -benzo[d][1,2,3]triazol-1-yl)-2-(phenyl-
amino)ethanone (8a). Yield 62% m.p. 181 C. IR (KBr):
m = 3360 (1NH), 3110 (CH aromatic), 2965 (CH aliphatic),
1610 (1C = O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 4.75 (s, 1H, NH, D2O exchangeable), 5.69 (s,
1H, CH), 6.43–7.98 (m, 13H, aromatic ring) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS): d = 78.9 (CH), 112.3
(CH), 112.6, 116.9, 128.4, 128.5, 128.6, 128.7, 128.8, 128.9,
129.0, 1289.1, 129.3, 129.4, (phenyl carbons), 130.7, 133.0,
134.0, 140 (C-1,2,3 triazole), 143.5 (C-phenyl), 200.0 (C‚O);
MS: m/z= 420 (M+, 20), 419 (20), 391 (15), 375 (40), 358
(10), 335 (15), 316 (45), 254 (45), 191 (40), 185 (40), 169 (30),
155 (40), 147 (45), 133 (40), 124 (50), 109 (48), 95 (40), 85
(55), 71 (65), 65 (60), 57 (100), 43 (70), 41 (60), 40 (20). Anal.
for C20H15N7O calcd. C 65.03, H 4.09, N, 26.54; Found C
65.00, H 4.07, N, 26.55.
2.2.2.5. 2-(p -Tolylamino)-1,2-di(1H-benzo[d][1,2,3]triazol-
1-yl)-ethanone (8b). Yield 60% m.p. 162 C. IR (KBr):
m = 3371 (1NH), 3067 (CH aromatic), 2921 (CH aliphatic),
1709 (1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 2.35 (s, 3H, CH3), 4.76 (s, 1H, NH, D2O exchange-
able), 5.46 (s, 1H, CH), 6.39–7.98 (m, 12H, aromatic ring)
ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS): d =
20.9 (CH3), 78.9 (CH), 112.2 (CH), 112.4 (CH), 126.1, 128.1,
128.2, 128.3, 128.4, 128.5, 128.6, 128.7, 129.0, 130.0, 130.2
(phenyl carbons), 133, 134.0, 140 (C-1,2,3 triazole), 140.5 (C-
phenyl carbons), 200.2 (C‚O); MS: m/z= 383 (M+, 15),
378 (30), 355 (25), 319 (50), 297 (20), 291 (50), 274 (25), 264
(35), 239 (55), 231 (10), 211 (25), 210 (35), 185 (35), 169 (30),
153 (15), 133 (15), 119 (20), 107 (100), 91 (80), 80 (70), 65
(30), 44 (40), 40 (10). Anal. for C21H17N7O calcd. C 65.79,
H 4.47, N, 25.57; Found C 65.77, H 4.45, N, 25.55.
2.2.2.6. 2-(4-Bromophenylamino)-1,2-di(1H -benzo[d][1,2,3]-
triazol-1-yl)ethanone (8c). Yield 69% m.p. 138 C. IR (KBr):
m = 3365 (1NH), 3113 (CH aromatic), 2962 (CH aliphatic),
1606 (1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 4.72 (s, 1H, NH, D2O exchangeable), 5.68 (s,
1H, CH), 7.54–7.77 (m, 12H, aromatic ring) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS): d = 78.9 (CH), 111.5,
114.5, 114.6, 128.3, 128.4, 128.5, 128.6, 128.7, 128.8, 128.9,
129.1 (phenyl carbons), 130.6 (1,2,3 triazole), 132.6, 132.7
(phenyl carbons), 133, 134.2, 140.1 (1,2,3 triazole), 142.4 (phe-
nyl carbon), 200.1 (C‚O); MS: m/z= 449 (M+2, 8), 447
(M+, 28), 450 (10), 420 (10) 419 (20), 391 (15), 375 (40), 358
(10), 335 (15), 316 (45), 254 (45), 191 (40), 185 (40), 169 (30),
155 (40), 147 (45), 133 (40), 124 (50), 109 (48), 95 (40), 85
(55), 71 (65), 65 (60), 57 (100), 43 (70), 41 (60), 40 (20). Anal.for C20H14BrN7O calcd. C 53.59, H 3.15, N, 21.87; Found C
53.57, H 3.14, N, 21.85.
2.2.2.7. 2-(Phenylamino)-1,2-bis(2-thioxobenzo[d ]thiazol-
3(2H)-yl)ethanone (9a). Yield 63% m.p. 190 C. IR (KBr):
m = 3365 (1NH), 3115 (CH aromatic), 2960 (CH aliphatic),
1615 (1C‚O), 1470 (1C‚S) cm1. 1H NMR (300 MHz,
CDCl3-d6, 25 C, TMS): d = 4.14 (s, 1H, NH, D2O
exchangeable), 4.70 (s, 1H, CH), 6.42–7.04 (m, 13H, aromatic
ring) ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS): d =
78.8 (CH), 112.3 (CH), 112.5 (CH), 116.9, 120.7,
124.4, 124.6, 124.8, 125.5, 125.6, 125.7, 129.3, 129.4, 129.5,
129.6, 129.8, 140.1, 141.5, 143.5 (phenyl carbons), 168.2
(amide), 193, 193.9 (thioamide); MS: m/z= 465 (M+, 20),
453 (20), 435 (10), 420 (10) 419 (20), 421 (12), 408 (15), 396
(15), 381 (05), 368 (25), 354 (20), 336 (40), 332 (10), 320 (35),
306 (15), 280 (10), 274 (40), 254 (60), 249 (80), 233 (15), 218
(50), 206 (32), 193 (60), 168 (35), 167 (62), 144 (85), 139 (45),
115 (60), 105 (55), 105 (52), 91 (45), 78 (60), 63 (80), 57
(100), 43 (70), 41 (60), 40 (20). Anal. for C22H15N3OS4 calcd.
C 56.75, H 3.25, N, 9.02; Found C 56.74, H 3.27, N, 9.00.
2.2.2.8. 2-(p-Tolylamino)-1,2-bis(2-thioxobenzo[d]thiazol-3-
(2H)-yl)ethanone (9b). Yield 60% m.p. 200 C. IR (KBr):
m = 3377 (1NH), 3066 (CH aromatic), 2961 (CH aliphatic),
1610 (1C‚O), 1473 (1C‚S) cm1. 1H NMR (300 MHz,
CDCl3-d6, 25 C, TMS): d = 2.37 (s, 3H, CH3), 4.27 (s, 1H,
NH, D2O exchangeable), 4.61 (s, 1H, CH), 6.60–7.48
(m, 12H, aromatic ring) ppm; 13C NMR (100 MHz, DMSO-
d6, 25 C, TMS): d = 20.9 (CH3), 78.8 (CH), 112.2, 112.4,
120.7, 120.9, 124.4, 124.8, 125.5, 125.6, 125.7, 126.1, 129.3,
129.4, 129.5, 130.0, 130.2, 140.1, 140.5, 141.7 (phenyl carbons),
168.2 (C‚O), 193.2, 194.0 (thioamide); MS: m/z= 480 (M+,
20), 466 (20), 453 (20), 435 (10), 421 (12), 408 (15), 396 (15),
381 (05), 368 (25), 354 (20), 336 (40), 332 (10), 320 (35), 306
(15), 280 (10), 274 (40), 254 (60), 249 (80), 233 (100), 218
(50), 206 (32), 193 (60), 168 (35), 167 (62), 144 (85), 139 (45),
115 (60), 105 (55), 105 (52), 91 (45), 78 (60), 63 (80), 44 (78),
41 (50), 40 (25). Anal. for C23H17N3OS4 calcd. C 57.59, H
3.57, N, 8.76; Found C 57.57, H 3.58, N, 8.77.
2.2.2.9. 2-(4-Bromophenylamino)-1,2-bis(2-thioxobenzo[d]
thiazol-3(2H)-yl)ethanone (9c). Yield 72% m.p. 182 C. IR
(KBr): m = 3405 (1NH), 3095 (CH aromatic), 2923 (CH ali-
phatic), 1648 (1C‚O), 1493 (1C‚S) cm1. 1H NMR
(300 MHz, CDCl3-d6, 25 C, TMS): d = 4.40 (s, 1H, NH,
D2O exchangeable), 4.80 (s, 1H, CH), 6.80–7.90 (m, 12H, aro-
matic ring) ppm; 13C NMR (100 MHz, DMSO-d6, 25 C,
TMS): d = 78.8 (CH), 111.5, 114.5, 114.7, 120.7, 124.4,
124.6, 124.8, 125.5, 125.6, 125.8, 129.3, 129.4, 129.5, 132.6,
132.8, 140.1, 141.7, 142.5 (phenyl carbons), 168.2 (C‚O),
193.2, 194.1 (thioamide); MS: m/z= 544 (M+2, 7), 543
(M+, 23), 514 (15) 516 (10), 510 (10), 496 (10), 481 (10), 460
(10), 439 (10), 419 (20), 391 (15), 375 (40), 358 (10), 335 (15),
305 (10), 284 (50), 269 (40), 258 (65), 242 (30), 225 (70), 211
(20), 198 (25), 183 (25), 169 (40), 167 (65), 150 (50), 136 (55),
124 (57), 127 (60), 108 (65), 90 (70), 71 (80), 57 (100), 43
(85), 41 (50), 40 (20). Anal. for C22H14BrN3OS4 calcd. C
48.53, H 2.59, N, 7.72; Found C 48.50, H 2.60, N, 7.70.
2.2.2.10. 2-(Diphenylamino)-N,N-diphenyl-2-(phenylamino)-
acetamide (10a). Yield 57% m.p. 112 C. IR (KBr):
NN
O
C
R Br
O
HN O
N
H
N
N
N
H
S
S
N
H
PhPh
NH
N
N
O
O
NH
NH
N
S
S
R NH
N
N
Ph
Ph
Ph
Ph
2 a-c
3
4
5
6
7a-c
8a-c
9a-c
10a-c
R; a = phenyl, b = p-tolyl, c = p-bromophenyl
R
R
N N
N
O
N
N
N
O
R
N
S
S
O
O
Scheme 1 Formation of amide derivatives 7–10.
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1610 (1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 4.10 (s, 1H, NH, D2O exchangeable), 4.75 (s,
1H, CH), 6.43–7.64 (m, 25H, aromatic ring) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS): d = 84.5 (CH), 112.3,
112.3, 116.9, 117.0, 117.2, 117.3, 117.4, 117.5, 117.6, 117.7,
117.9, 118.0, 118.2, 118.3, 118.5, 129.3, 129.4, 129.5, 129.6,
129.7, 129.8, 129.9, 130.0, 130.1, 130.2, 143.0, 143.1, 143.2,
143.3, 143.4 (phenyl carbons), 163.7 (C‚O); MS: m/z= 469
(M+, 20), 465 (10), 453 (20), 435 (10), 420 (10) 419 (20), 421
(12), 408 (15), 396 (15), 381 (05), 368 (25), 354 (20), 336 (40),
332 (10), 320 (35), 306 (15), 280 (10), 274 (40), 254 (60), 249
(80), 233 (15), 218 (50), 206 (32), 193 (60), 168 (35), 167 (62),
144 (85), 139 (45), 115 (60), 105 (55), 105 (52), 91 (45), 78
(60), 63 (80), 57 (10), 43 (100), 41 (60), 40 (20). Anal. for
C32H27N3O calcd. C 81.85, H 5.80, N, 8.95; Found C 81.87,
H 5.82, N, 8.93.
2.2.2.11. 2-(Diphenylamino)-N,N-diphenyl-2-(p-tolylamino)-
acetamide (10b ). Yield 50% m.p. 215 C. IR (KBr):
m = 3380 (1NH), 3060 (CH aromatic), 2965 (CH aliphatic),
1615 (1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 2.36 (s, 3H, CH3), 4.35 (s, 1H, NH, D2O exchange-
able), 4.74 (s, 1H, CH), 6.43–7.04 (m, 24H, aromatic ring)
ppm; 13C NMR (100 MHz, DMSO-d6, 25 C, TMS):
d = 20.9 (CH3), 84.5 (CH), 112.2, 112.4, 117.1, 117.2, 117.3,117.4, 117.5, 117.6, 117.7, 117.9, 118.0, 118.1, 118.2, 118.3,
126.1, 129.4, 129.5, 129.6, 129.7, 129.8, 129.9, 130.1, 130.2,
130.3, 130.4, 140.5, 143.2, 143.4, 143.2, 143.4 (phenyl carbons),
163.9 (C‚O); MS: m/z= 483 (M+, 20), 455 (20), 453 (10),
435 (10), 421 (12), 408 (15), 396 (15), 381 (05), 368 (25), 354
(20), 336 (40), 332 (10), 320 (35), 306 (15), 280 (10), 274 (40),
254 (60), 249 (80), 235 (100), 218 (50), 206 (32), 193 (60), 168
(35), 167 (62), 144 (85), 139 (45), 115 (60), 105 (55), 105 (52),
91 (45), 78 (60), 63 (80), 44 (78), 41 (45), 40 (25). Anal. for
C33H29N3O calcd. C 81.96, H 6.04, N, 8.69; Found C C
81.95, H 6.05, N, 8.67.
2.2.2.12. 2-(4-Bromophenylamino)-2-(diphenylamino)-N,N-
diphenylacetamide (10c). Yield 59% m.p. 210 C. IR (KBr):
m = 3382 (1NH), 3090 (CH aromatic), 2921 (CH aliphatic),
1595 (1C‚O) cm1. 1H NMR (300 MHz, CDCl3-d6, 25 C,
TMS): d = 4.40 (s, 1H, NH, D2O exchangeable), 4.89 (s, 1H,
CH), 6.95–7.82 (m, 24H, aromatic ring) ppm; 13C NMR
(100 MHz, DMSO-d6, 25 C, TMS): d = 84.5 (CH), 111.5,
114.5, 114.7, 117.1, 117.2, 117.3, 117.4, 117.5, 117.6, 117.7,
117.8, 118.0, 118.1, 118.2, 118.3, 129.4, 129.5, 129.6, 129.7,
129.8, 129.9, 130.0, 130.3, 132.6, 132.7, 142.5, 143.2, 143.4,
143.6, 143.7 (phenyl carbons), 163.8 (C‚O); MS: m/z= 549
(M+2, 20), 547 (M+, 10), 520 (20), 521 (10), 500 (10), 480 (20),
467 (10), 439 (12), 422 (10), 411 (10), 383 (10), 368 (12), 350
(15), 349 (20), 323 (10), 311 (10), 294 (10), 257 (15), 239 (15),
239 (10), 225 (10), 211 (12), 197 (10), 183 (30), 169 (25), 155
(30), 141 (30), 127 (40), 113 (42), 99 (50), 85 (70), 71 (80), 57
(100), 43 (82), 41 (50), 40 (15). Anal. for C32H26BrN3O calcd.
C 70.08, H 4.78, N, 7.66; Found C 70.09, H 4.76, N, 7.68.
2.3. Anti-tubercular assay
The anti-tubercular activity of the test compounds was evalu-
ated against the standard strain of Mycobacterium tuberculae
H37Rv (Sahm and Washington, 1991). Antibiotic standards
used were streptomycin and pyrazinamide. The procedure fol-
lowed for anti-tubercular activity involves the use of Middle-
brook 7H-9 broth and standard strain of M. tuberculosis
H37Rv. The basal mediumwas prepared according tomanufac-
turer’s instructions (Hi-Media) and sterilized by autoclaving.
Then broth (4.5 ml) was poured into each one of the sterile bot-
tles. To this, ADC (0.5 ml) supplement was added. The supple-
ment consists of catalase, dextrose and BSA fraction v. Then a
stock solution was prepared (10 mg/ml). From this appropriate
amount of solution was transferred to media bottles to achieve
ﬁnal concentrations of 25, 50, 100 lg/ml. Finally 10 ll suspen-
sion of M. tuberculosis H37Rv strain (1 lakh organisms/ml ad-
justed by McFarmland’s turbidity standard) was transferred
to each of the tubes and incubated at 37 C. Along with this,
one growth control without compound and drug controls were
also set up. The bottles were inspected for growth twice a week
for a period of three weeks. The appearance of turbidity indi-
cated the growth and infers the resistance to the compound.
The growth was conﬁrmed by making a smear from each bottle
and performing a ZN strain Scheme 1.3. Results and discussion
3-Arylsydnone 1a–c was brominated in acetic acid and the
4-bromo-3-arylsydnones (2a–c) formed was further reacted
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(7–10). The proposed mechanism of the formation of the ﬁnal
compounds is given in Scheme 2 (Browne and Harrity, 2010).
The initial attack of the ﬁrst molecule of nitrogen of the amine
on the C4 carbon of the sydnone 2a–c followed by the loss of
the HBr gave an intermediate 12. Another molecule of second-
ary amine attacks the carbonyl carbon atom of the resonance
hybrid of 12 i.e., 13, to form the intermediate 14 which under-
goes elimination of NO+ ion and subsequent protonation gave
the ﬁnal product (7–10). The formation of title compounds
(7–10) was conﬁrmed by IR, 1H NMR, MS and elemental
analyses and the data are reported in the experimental section.
All these compounds have shown a common strong absorption
band for NH  3360–3482 cm1, CH aromatic  3060–
3286 cm1, CH aliphatic  2919–2965 cm1, C‚O  1595–
1709 cm1, respectively. Compounds 9a, 9c, 10b have
exhibited a sharp band 1470–1493 cm1, for C‚S.
The 1H NMR spectral analysis of the title compounds
exhibited the following observations. All the compounds have
shown a singlet in the range 4.10–4.75 ppm. for NH proton
(D2O exchanged), down ﬁeld shift for the proton CH attached
to carbonyl displayed a singlet in the range 4.70–5.69 ppm,
aromatic protons appeared as multiplets in the range 6.32–
7.98 ppm. The compounds 7a–c have shown multiplets for
the methylene protons of morpholine ring in the range 3.15–
3.39 ppm and 3.48–3.67 ppm, respectively. Compounds 8b,
9b, and 10b have shown a singlet for methyl protons attached
to phenyl ring in the range 2.35–2.37 ppm. In the electron im-
pact studies all the compounds showed molecular ion peaks at
their respective m/z.
3.1. Biological activity
To qualify as a drug candidate, a new molecule has to be ana-
lysed for the parameters set by Lipinski’s rule (Lipinski et al.,
1997) of ﬁve using Osiris property explorer. Lipinski’s rule of
ﬁve is a rule of thumb to evaluate drug likeliness or to deter-
mine if a compound with a certain pharmacological or biolog-
ical activity has properties that would make it a likely orally
active drug in humans. The molecular properties are impor-
tant for drug pharmacokinetics in human body, including
their absorption, distribution, metabolism and excretion
(ADME). The rule is important for drug development where
pharmacologically active lead structure is optimized step wisefor increased activity and selectivity, as well as drug like
properties as described by Lipinski rule. The modiﬁcation of
the molecular structure often leads to drugs with higher
molecular weight, more rings, more rotatable bonds and
higher lipophilicity. The rule states that in general an orally
active drug has not more than 5 hydrogen bond donors,
and not more than 10 hydrogen acceptors, a molecular weight
under 500 and the partition coefﬁcient c log P less than 5 did
not title compounds do not violate the Lipinski rule and they
fall well in the range as mentioned when evaluated by the Osi-
ris property explorer (Table 1) which lead us to evaluate the
compounds experimentally. Promising results were shown
for all compounds as the compounds were shown as safe
drugs without any effects as mentioned in Osiris property ex-
plorer. None of the compounds were found to be tumourigen-
ic, irritant or reproductive effect drug. Compounds (7b, 8b, 9c,
and 9d) with a methyl group on the phenyl ring have shown
mutagenic effect. Rest of all the compounds has not shown
any mutagenic effect. Almost all the title compounds showed
c log P well within the range and also certain compounds have
molecular weights less than 500. The drug likeliness ranged
from 1.71 to 2.28 where as the drug score is in the range
0.1–0.82. The compounds 7a, 7b, 10a which have electron
donating groups, such as phenyl, halogen atom and morpho-
line show good drug scores as depicted in Table 2. The com-
pounds 8a–b, 9d, 10a–b and d which have benzotriazole and
diphenyl amine groups showed negative drug likeliness and
as a result the drug score was less, and the presence of a
halogen atom did not magnify the effect, where as the
compounds 9a and 10c which have benzothaizoline-2-thione
moiety have also shown diversiﬁed effects based on drug like-
liness and drug score but c log P values are well within the
range as mentioned by the rule.
In case of anti-tubercular activity studies, depicted in Table
2 the compounds with electron withdrawing atom such as bro-
mine, heterocycles viz., morpholine and benzotriazole, (7a–b,
8a, 8c and 10a), have exhibited excellent inhibition (MIC) at
less than or equal to 5 lg/ml concentration. The compounds
with benzotriazole and diphenylamine 9d, 10a–c showed mod-
erate inhibition in the range of 10–12 lg/ml. The compounds
9a–c with benzothiazoline-2-thione showed activity only at
more than 20 lg/ml concentrations as compared to standards
used viz., streptomycin (7.5 lg/ml) and pyrazinamide (10 lg/
ml), respectively. Encouraging activity is attributed to the pres-
Table 1 Pharmacological parameters for bioavailability of the
compounds (7–10).
Entry No. c log P Drug likeliness Drug score
7a 0.09 2.23 0.90
7b 0.23 2.28 0.54
7c 0.61 1.72 0.82
8a 2.33 0.16 0.46
8b 2.65 0.04 0.26
8c 3.03 0.65 0.33
9a 5.52 1.70 0.27
9b 5.84 1.79 0.15
9c 6.22 1.22 0.19
10a 5.27 1.14 0.18
10b 5.59 1.13 0.10
10c 5.97 1.71 0.13
Table 2 Anti-tubercular activity of the synthesized com-
pounds (strain H37Rva).
Entry No. MIC (lg/ml)
7a 4.5
7b 4.0
7c 3.5
8a 4.5
8b 6.0
8c 5.0
9a 20
9b 25
9c 25
10a 10
10b 12
10c 12
Standard: streptomycin 7.5 lg/ml, pyrazinamide 10 lg/ml.
All compounds tested at concentration of 5, 10, 25 lg/ml.
The active compounds are marked in bold letters.
a ATCC number.
Synthetic utility of sydnones to couple pharmacologically important heterocycles for antitubercular activity 905ence of cycloalkylating chains (e.g., morpholine ring) and with
electron withdrawing substituent such as bromo appended to
phenyl ring.
4. Conclusion
In conclusion, we have developed a simple and efﬁcient meth-
od for the synthesis of novel amide derivatives incorporated
with the bioactive heterocycles viz., morpholine, benzotriazole
and benzothiazolin-2-thione. We also believe that the proce-
dural simplicity, the efﬁciency and the easy accessibility of
the reaction partners give access to a wide array of heterocyclic
frameworks. The results of the anti-tubercular screening reveal
that among all of the 12 compounds six compounds showed
good inhibition while the other nine compounds displayed
moderate to low inhibition.Acknowledgements
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